Lyell Immunopharma's total assets for Q3 2024 were $619.22M, a decrease of -5.34% from the previous quarter. LYEL total liabilities were $88.52M for the fiscal quarter, a 1.00% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.